Overview

Catherine Longeval specialises in dispute resolution, both before the Belgian courts and before arbitral tribunals (mainly CEPANI). She advises clients on a wide range of issues, including life sciences law. Her expertise in this area covers laws governing medicines, biotech products, medical devices, cosmetics and food supplements, among other aspects.

She also specialises in unfair market practices, distribution law, product liability, employment law and general commercial law.

Catherine began her professional career in October 1989. Prior to joining Van Bael & Bellis in 1994, she worked as an associate with a leading Brussels law firm. 

She regularly lectures and writes on life sciences regulatory matters and procedural law matters. She often speaks at conferences.

Languages

Dutch, English, French, German (passive knowledge)

Recommendations

  • Chambers Global and Chambers Europe for Dispute Resolution
  • Chambers Europe – ‘Leaders In Their Field’ (Dispute Resolution) 
  • Expert Guides – Guide to the World’s Leading Litigation Lawyers
  • PLC for EU Life Sciences – Regulatory
  • PLC for EU Life Sciences – Competition/Anti-trust
  • PLC for Dispute Resolution 
  • PLC for Belgium Life Sciences – Regulatory
  • Legal 500 for Employment law
  • Legal 500 for Dispute Resolution
  • European Legal Experts for Litigation
  • Who’s Who Legal for Life Sciences
  • LMG Life Sciences (Europe) – Life Sciences Star
  • Best Lawyers – Litigation  

Education

  • University of Brussels (ULB), Master of Laws, 1989 
  • University of Leuven, Master of Laws, 1987

Publications

Contributor to Van Bael & Bellis' Business Law Guide to Belgium (Kluwer Law International/Bruylant, 2003).

Co-author of PLC's Life Sciences Handbook, Chambers' Pharmaceutical Advertising Guide, and dispute resolution section of Chambers' Litigation guide. 

Professional Memberships

Member of CEPINA (Belgian Centre for Mediation and Arbitration)
Member of the Brussels Pharma Law Group
Member of the European Employment Lawyers Association
Member of the International Bar Association

Bar Admission

Brussels

Notable assignments

  • Representing a global pharmaceutical company in the context of “extreme urgency” suspension proceedings before the Council of State, aimed at the suspension and annulment of a tender decision of the Office de la Naissance et de l’Enfance (ONE) granted in favour of a competitor of our client.

  • Representing a global logistics company in proceedings initiated by an international organisation and the Belgian State following our client’s attachment of assets in a case which raises complex issues under international and procedural law.

Publications and insights

Sign up for updates
    • 27/11/2020
    • Articles

    European Commission Fines Cephalon and Teva On Account of "Pay-for-Delay" Patent Settlement Agreement

    On 26 November 2020, the European Commission (the Commission) brought to an end a long running competition case by finding against Cephalon and Teva on account of a “pay-for-delay” patent settlement agreement involving modafinil, the active substance of a sleeping disorder medicine (see, attached Commission press release).

    Read more
    • 26/11/2020
    • Articles

    European Commission Presents Pharmaceutical Strategy for Europe

    On 25 November 2020, the European Commission (the Commission) unveiled its Pharmaceutical Strategy for Europe (PSE), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders (see, attached Commission Communication (2020) 761 final; Commission press release; and Commission Q&A). The announcement follows an extensive period of consultation, study and preparation (see, Van Bael & Bellis Life Sciences News Alerts of 20 October 2020; 12 August 2020; 17 June 2020; 3 June 2020; and 28 May 2020).

    Read more
    • 25/11/2020
    • Articles

    Potential Covid-19 Vaccine Supplier Moderna Sixth Contract Partner of European Commission

    On 24 November 2020, European Commission President von der Leyen released a statement announcing that she would approve a sixth agreement with a supplier of a potential Covid-19 vaccine (see, attachment). The Commission’s new contract partner is Moderna. Under the agreement, the Commission will have the right to buy up to 160 million doses of the vaccine, if and when that product obtains a marketing authorisation from the European Medicines Agency. In recent days, the Commission announced similar deals with CureVac (see, Van Bael & Bellis Life Sciences News Alert of 17 November 2020) and with BioNTech and Pfizer (see, Van Bael & Bellis Life Sciences News Alert of 12 November 2020). The Commission President suggested that a seventh agreement is being negotiated which paves the way for the creation in Europe of “one of the most comprehensive COVID-19 vaccine portfolios in the world”.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *